Arca
Skip to content
Tools
Tools

Neuroblastoma

Drug research and approvals for neuroblastoma: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 111 studies of neuroblastoma are recruiting on ClinicalTrials.gov, Health Canada has authorized 25 drug trials for it since 2013, FDA has 3 approved and 43 open orphan designations naming it, and the EU has 1 authorised medicine for it.

  • Recruiting worldwide: 111
  • Trials authorized in Canada: 25
  • FDA orphan approvals: 3
  • EU medicines: 1

Recruiting now

Newest posted first, of 111 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition or a subtype of it, from ChEMBL's drug indications

Approved 4

Phase 3 12 of 24

Phase 2 12 of 39

Phase 1 or earlier 12 of 44

How its trials ended

592 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 135 whose ending is known, 24% met their primary endpoint, 9% missed it and 67% stopped early.

  • Completed, result not reported24341%
  • Ongoing16227%
  • Status unknown529%
  • Stopped: other or unclear478%
  • Met its primary endpoint336%
  • Stopped: enrollment or feasibility224%
  • Missed its primary endpoint122%
  • Stopped: sponsor or business decision112%
  • Stopped: lack of efficacy71%
  • Stopped: funding31%

Trials authorized in Canada

The 10 newest of 25; search them all in Canada trials
Apr 10, 2026A phase 2/3 study to characterize and evaluate the efficacy, safety, and tolerability of hu 14.18k322a treatment given in combination with chemotherapy in…RPL001 / Irinotecan hydrochloride / TemozolomideRenaissance PharmaceuticalsOngoing
Jun 19, 2024A phase 3 study of dinutuximab added to intensive multimodal therapy for children with newly diagnosed high-risk neuroblastomaUnituxin / Etopophos / LeukineChildrens Oncology GroupOngoing
Feb 24, 2023A phase 1b/2 study of abemaciclib in combination with irinotecan and temozolomide (part a) and abemaciclib in combination with temozolomide (part b) in…Abemaciclib (LY2835219)/ Irinotecan/ Temozolomide/ Dinutuximab/ SargramostimEli LillyClosed
Sep 2, 2022A phase II study of naxitamab added to induction therapy for subjects with newly diagnosed high-risk neuroblastomaNaxitamab / Sargramostim, gm-csf / CeritinibBeat Childhood CancerOngoing
Jul 4, 2022Study of talazoparib for metastatic relapsed neuroblastoma: a pediatric oncology precision medicine studyTalazoparibC17 CouncilClosed
Apr 8, 2021A multicenter phase 2/3 trial of the efficacy and safety of intracerebroventricular radioimmunotherapy using 131i-omburtamab for neuroblastoma central nervous…131I-omburtamabY-mAbs TherapeuticsClosed
Feb 25, 2021A pilot study of dinutuximab, sargramostim (gm-csf), and isotretinoin in combination with irinotecan and temozolimide in post-consolidation setting for…Irinotecan/ Temozolomide/ SargramostimChildrens Oncology GroupClosed
Oct 23, 2020Pilot study of 68ga-dotatate pet/ct and 123i-mibg scintigraphy imaging of neuroblastoma68GA-dotatateCentre Hospitalier Universitaire De SherbrookeOngoing
Sep 21, 2020Phase II trial of eflornithine (DFMO) and etoposide for relapsed/refractory neuroblastomaEflornithine / Etoposide / Etoposide phosphateBeat Childhood Cancer Research ConsortiumOngoing
Sep 10, 2020Peds-plan – pediatric precision laboratory advanced: a study using molecular guided therapy with induction chemotherapy followed by a randomized controlled…Eflornithine / SargramostimBeat Childhood Cancer Research ConsortiumOngoing

FDA orphan designations

Approved first, then open designations, newest first; 15 of 46
Dec 13, 2023IwilfinTo reduce the risk of relapse in adult and pediatric patients with high-risk neuroblastoma (HRNB) who have demonstrated at least a partial…Uswm, LLCApproved
Nov 25, 2020Danyelza®In combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), for the treatment of pediatric patients 1 year of age and…Y-mAbs Therapeutics, Inc.Approved
Mar 10, 2015UnituxinFor use in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2) and 13-cis-retinoic acid (RA),…United Therapeutics CorporationApproved
Aug 13, 2026A small molecule degrader of RNA-binding motif protein 39Treatment of neuroblastomaSEED Therapeutics Inc.Designated
Sep 23, 2025DicaprateTreatment of neuroblastomaAminex Therapeutics, Inc.Designated
Feb 21, 2025A genetically modified salmonella comprising of Diphtheria…Treatment of neuroblastomaShanghai Salvectors Biotechnology LTD.Designated
Oct 24, 2024PHOX2B PC-CAR T CellsTreatment of neuroblastomaHula Therapeutics Inc.Designated
Oct 24, 2024SilmitasertibTreatment of neuroblastomaSenhwa Biosciences, Inc.Designated
Oct 19, 2024OpaganibTreatment of neuroblastomaApogee Biotechnology CorporationDesignated
Aug 21, 2024OpaganibTreatment of neuroblastomaRedHill Biopharma Ltd.Designated
Apr 8, 2024Humanized anti-GD2 monoclonal antibodyTreatment of NeuroblastomaRenaissance Pharma, Ltd.Designated
Feb 26, 2024Bispecific anti-GD2/anti-B7-H3 monoclonal antibodyTreatment of NeuroblastomaInvenra Inc.Designated
Jul 31, 2023DTPA[Indium-111]-dinutuximab-IRDye800CWDiagnostic for the management of neuroblastomaUniversity of PittsburghDesignated
Nov 25, 2022RibociclibTreatment of neuroblastomaNovartis Pharmaceuticals CorporationDesignated
Nov 8, 202264-fluoro-36-methox-27-methyl-5-thia-4,8-diaza-2(4,6)-tieno[…Treatment of NeuroblastomaAUM BiosciencesDesignated

Medicines authorised in the EU

Newest first
AuthorisedMedicineHolderEPAR
May 8, 2017Qarziba (previously Dinutuximab beta EUSA and Dinutuximab beta Apeiron)Dinutuximab beta · orphanRecordati Netherlands B.V.EMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.